AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is currently conducting a Phase Ib clinical study titled A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET). The study aims to evaluate the effects of AZD3427 on renal perfusion in patients with heart failure and reduced renal function, which could have significant implications for treating these conditions.
The intervention being tested is AZD3427, a biological treatment administered via subcutaneous injection. The study also involves the use of radiolabelled ligands for PET imaging and saline or dopamine as controls. The primary goal is to assess changes in renal perfusion and other biomarkers of renal function.
This interventional study is randomized and employs a parallel assignment model. It is double-blind, meaning both participants and investigators are unaware of who receives the treatment or placebo. The primary purpose is treatment-focused.
The study began on October 15, 2024, with an estimated completion date not yet specified. The latest update was submitted on August 14, 2025. These dates are crucial for tracking the progress and potential release of results.
The outcome of this study could influence AstraZeneca’s stock performance by potentially enhancing its portfolio in the heart failure treatment market. Positive results might boost investor confidence, while negative outcomes could have the opposite effect. Competitors in the pharmaceutical industry will be watching closely, as advancements in this area could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.